Sponsor & Developer Portfolio
Dynavax
Clinical development pipeline, platform architecture, and registered trial tracking for Dynavax vaccine candidates.
4
Candidates
4
Target Diseases
4
Linked Studies
Development Phase Distribution
Phase 2 Clinical Trial: 2 Discontinued / Inactive: 2
Platform Technologies
Biological (unspecified platform): 4
Target Pathogens & Indications
Hepatitis B Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis Rhinitis, Allergic, Seasonal Varicella / Zoster
Vaccine Pipeline Candidates (4)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-1018-iss-hbsag-single-dynavax-technologies-corporation
1018 ISS-HBsAg-Single
Target: Hepatitis B
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2008-08 (registry estimate)
Discontinued / Inactive
ctgov-amb-a-1-immunostimulatory-oligodeoxyribonucleotide-conjugate-dyn
Histamine base
Target: Rhinitis, Allergic, Seasonal
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2007-05 (registry estimate)
Phase 2 Clinical Trial
ctgov-z-1018-dynavax-technologies-corporation
Z-1018
Target: Varicella / Zoster
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2027-11 (registry estimate)
Phase 2 Clinical Trial
ctgov-rf1v-1018-dynavax-technologies-corporation
rF1V-1018
Target: Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2027-01-29 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.